Hillhurst Bio
Wednesday, June 05, 2024
Multiple Therapeutics
Company Presentation Theater 2
Hillhurst Bio is a clinical stage company developing novel oral liquid drugs, using its proprietary GLASS platform to enable the oral delivery of medicines that previously could only be delivered by inhalation. Our lead drug product, HBI-002, targets treatment of sickle cell disease and Parkinson’s disease, and our follow-on non-opioid drug, HBI-201, targets acute pain.
Company Website:
http://www.hillhurstbio.com
Lead Product in Development:
HBI-002
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Company HQ City
Montrose
Company HQ State
CA 91020
Company HQ Country
United States
CEO/Top Company Official
Andrew Gomperts, JD MBA
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())